Company: PGEN
Filing Date: 2025-08-19
Form Type: S-3
Source: 0000950103-25-010472
Chunk: 6

Company: PRECIGEN, INC.
Filing Date: 2025-08-19
Form: S-3
Chunk 6
---
 on our UltraCAR-T platform.
We have completed enrollment in the Phase 1b clinical trial of PRGN-3006. As part of the strategic prioritization of our pipeline, we
have paused enrollment in the PRGN-3005 and PRGN-3007 clinical trials.

On August 15, 2025, we announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).

Our Corporate Information

We are a Virginia corporation formed in 1998 and
our principal executive offices are located at 20374 Seneca Meadows Parkway, Germantown, MD 20876, and our telephone number is (301) 556-9900.
Our website address is www.precigen.com. Information on or accessible through our website is not incorporated by reference herein
and does not form a part of this prospectus.

<div align='center'>1</div>

The Offering

| Shares of Common Stock offered by the selling stockholders    | 143,809,489 shares of Common Stock                                                                                                                                                                                                                                                                                                                                                                                |
| Shares of Preferred Stock offered by the selling stockholders | 79,000 shares of Preferred Stock                                                                                                                                                                                                                                                                                                                                                                                  |
| Terms of this offering                                        | The selling stockholders may sell, transfer or otherwise dispose of any or all of the shares of Common Stock and Preferred Stock offered by this prospectus from time to time as described under the caption “Plan of Distribution” in this prospectus.                                                                                                                                                           |
| Use of proceeds                                               | All proceeds from the sale of shares of Common Stock and Preferred Stock offered hereby will be for the account of the selling stockholders. We will not receive any proceeds from the sale of Common Stock or Preferred Stock offered pursuant to this prospectus. See the caption “Use of Proceeds” in this prospectus.                                                                                         |
| Risk factors                                                  | Investing in our securities involves a high degree of risk and purchasers of our securities may lose their entire investment. See the information under the caption “Risk Factors” on page 3 of this prospectus and the other information included elsewhere in this prospectus and incorporated by reference herein for a discussion of factors you should consider before deciding to invest in our securities. |
| Nasdaq Global Select Market symbol for our Common Stock       | PGEN                                                                                                                                                                                                                                                                                                                                                                                                              |

When we refer to the selling stockholders in this prospectus, we are referring to the